This Phase 2 randomized, double-blind, placebo-controlled clinical trial investigates whether alpha-linolenic acid (ALA) supplementation from flaxseed oil can prevent cognitive decline in older adults with amnestic mild cognitive impairment (MCI) who carry the APOE4 allele. The trial represents a precision medicine approach targeting the specific metabolic vulnerabilities of APOE4 carriers, who face significantly elevated risk for Alzheimer's disease and related dementia (ADRD).
The study is sponsored by Rutgers University under the leadership of Dr. Michal Schnaider Beeri, a renowned researcher in the field of Alzheimer's disease epidemiology and prevention. The trial addresses a critical gap in therapeutic options for the preclinical and early symptomatic stages of Alzheimer's disease, particularly in the high-risk APOE4 carrier population.
| Field |
Value |
| NCT ID |
NCT07392723 |
| Status |
Recruiting |
| Phase |
Phase 2 |
| Study Type |
Interventional |
| Allocation |
Randomized |
| Intervention Model |
Parallel Assignment |
| Masking |
Double-Blind, Quadruple-Masked |
| Enrollment |
20 participants (estimated) |
| Sponsor |
Michal Schnaider Beeri, Ph.D., Rutgers University |
| Duration |
6 months |
| Location |
Rutgers - Institute for Health, New Brunswick, New Jersey |
¶ APOE4 and Alzheimer's Disease Risk
The APOE gene encodes apolipoprotein E, a lipid transport protein crucial for cholesterol metabolism and neuronal repair. The APOE4 allele represents the strongest known genetic risk factor for late-onset Alzheimer's disease:
- Heterozygous APOE4 (one copy): 3-4× increased AD risk
- Homozygous APOE4 (two copies): 10-12× increased AD risk
- Population Frequency: ~25% of population carries at least one APOE4 allele
APOE4 carriers demonstrate distinct lipid metabolism abnormalities that contribute to neurodegeneration:
- Reduced DHA incorporation: APOE4 carriers show decreased brain DHA levels despite adequate dietary intake
- Impaired lipid transport: APOE4 protein has reduced affinity for lipoproteins
- Altered astrocyte function: APOE4 astrocytes demonstrate impaired cholesterol efflux
- Endogenous synthesis limitation: Reduced conversion of ALA to long-chain omega-3s (DHA, EPA)
APOE4 is associated with significant blood-brain barrier (BBB) dysfunction:
- Increased BBB permeability: APOE4 carriers show elevated water exchange across BBB
- Reduced MFSD2A expression: The major DHA transporter at the BBB is downregulated
- Cerebrovascular dysfunction: Impaired vascular reactivity and autoregulation
- Pericyte injury: APOE4 is associated with pericyte degeneration
This trial tests the hypothesis that high-dose ALA supplementation will:
- Enhance endogenous DHA synthesis: Despite the APOE4-associated conversion impairment, sufficient ALA substrate may overcome the bottleneck
- Improve BBB integrity: Omega-3 fatty acids support endothelial cell function and tight junction maintenance
- Reduce neuroinflammation: ALA and its derivatives exert anti-inflammatory effects
- Protect cerebrovascular health: Maintain cerebral blood flow and vascular reactivity
| Parameter |
Value |
| Intervention |
Flaxseed oil (Alpha-Linolenic Acid) |
| Dose |
2.6g ALA per day |
| Administration |
Oral, divided doses |
| Duration |
6 months |
| Formulation |
Flaxseed oil softgels or liquid |
| Parameter |
Value |
| Intervention |
Corn oil (iso-caloric placebo) |
| Administration |
Oral, matching volume |
| Duration |
6 months |
| Matching |
Caloric content and appearance |
The 2.6g/day ALA dose was selected based on:
- Epidemiological data: Higher ALA intake associated with reduced cognitive decline
- Safety profile: Well-tolerated at this dose range
- Conversion potential: Sufficient substrate to potentially enhance endogenous DHA synthesis
- Comparison to prior trials: Within range of doses tested in cardiovascular studies
- Age: 60 years and older
- Cognitive status: Amnestic mild cognitive impairment (MCI) diagnosis
- Genetic status: At least one APOE4 allele (confirmed by genotyping)
- Capacity: Ability to provide informed consent
- Availability: Willingness to complete 6-month study period
- Established AD diagnosis: Confirmed Alzheimer's disease diagnosis
- Significant neurological condition: Other causes of cognitive impairment
- Cardiovascular instability: Uncontrolled hypertension or recent cardiovascular events
- Omega-3 supplementation: Current use of omega-3 supplements (>1g/day)
- Bleeding disorders: Conditions affecting bleeding risk
- Allergy: Allergy to flaxseed or corn oil products
- Measure: Change in composite z-scores from baseline to 6 months
- Assessment: Comprehensive neuropsychological battery
- Domains: Memory, executive function, language, visuospatial
- MRI Metric: Water exchange rate constant (Kw) via MRI
- Significance: Quantifies BBB permeability in vivo
- Technique: Dynamic contrast-enhanced MRI or arterial spin labeling
- MFSD2A: Major facilitator superfamily domain containing 2A (DHA transporter)
- S100B: Calcium-binding protein, marker of BBB disruption
- GFAP: Glial fibrillary acidic protein, astrocyte activation marker
¶ Cognitive Domain-Specific Outcomes
- Episodic memory: Word recall, story memory
- Executive function: Trail making, Stroop test
- Processing speed: Digit symbol substitution
- Language: Verbal fluency, naming
- Cerebral blood flow: Arterial spin labeling MRI
- Brain vascular reactivity: BOLD signal response to vasodilatory challenge
- White matter hyperintensity volume: FLAIR MRI assessment
- ADRD biomarkers: p-tau217, Neurofilament Light Chain (NfL)
- Lipid profile: Total cholesterol, LDL, HDL, triglycerides
- Omega-3 markers: ALA, DHA, EPA levels in plasma/red blood cells
- Adverse events monitoring
- Laboratory values (lipid panel, liver function, renal function)
- Vital signs
ALA (18:3 n-3) is the plant-based omega-3 fatty acid that serves as a precursor to longer-chain omega-3s:
ALA (18:3 n-3)
↓ Δ6-desaturase (limited in humans)
EPA (20:5 n-3)
↓ elongation
DHA (22:6 n-3)
- ALA supplementation increases circulating phospholipid content
- Supports astrocyte lipid efflux via APOE-dependent pathways
- Improves neuronal lipid delivery for membrane maintenance
- Omega-3s incorporate into endothelial cell membranes
- Enhances tight junction protein expression
- Upregulates MFSD2A transporter expression
- Reduces prostaglandin E2 synthesis
- Decreases NF-κB activation in microglia
- Promotes resolution of neuroinflammation
- DHA is precursor to neuroprotectin D1 (NPD1)
- EPA-derived resolvins promote phagocytic clearance
- Membrane omega-3 enrichment protects against ferroptosis
¶ Expected Outcomes and Clinical Significance
Based on the biological rationale, the trial anticipates:
- Cognitive Preservation: Slower rate of cognitive decline in treatment vs. placebo
- BBB Protection: Reduced water exchange rate (improved BBB integrity)
- Biomarker Improvement: Increased blood omega-3 levels and reduced neuroinflammatory markers
If successful, this trial would establish:
- Precision Prevention: APOE4-targeted nutritional intervention
- Low-Cost Approach: Accessible dietary supplementation for at-risk individuals
- Mechanistic Validation: Proof-of-concept for lipid-based AD prevention
- Combination Potential: Foundation for combination with other prevention strategies
| Trial |
Population |
Dose |
Outcome |
| MAPT |
MCI/AD |
DHA+EPA 2g |
Negative |
| VITAL |
General >60 |
Fish oil 1g |
Negative (overall), positive (APOE4) |
| NCT07392723 |
APOE4+MCI |
ALA 2.6g |
Pending |
The key distinction is the focus on APOE4 carriers specifically and the use of ALA rather than preformed DHA/EPA, testing the endogenous conversion enhancement hypothesis.